RARE DISEASE
Distal renal tubular acidosis
Distal renal tubular acidosis
Distal renal tubular acidosis
Synonyms: Classic RTA, Familial distal primary acidosis, Renal tubular acidosis type 1, dRTA
Synonyms: Classic RTA, Familial distal primary acidosis, Renal tubular acidosis type 1, dRTA
Synonyms: Classic RTA, Familial distal primary acidosis, Renal tubular acidosis type 1, dRTA
Drug discovery
2
drugs
With orphan designations
Overview
Distal Renal Tubular Acidosis (dRTA) is a disorder of impaired urinary acidification in the distal nephron, causing hyperchloremic metabolic acidosis. It arises from genetic mutations (e.g., ATP6V1B1, SLC4A1) or secondary causes (autoimmune diseases, medications). Key features include hypokalemia, nephrolithiasis, nephrocalcinosis, and bone demineralization. Diagnosis involves urinary pH >5.3 despite systemic acidosis and confirmed via acid-loading tests [1][2][6][9].
Population
Rare; hereditary forms (autosomal dominant/recessive) are more prevalent in consanguineous populations (e.g., North Africa, Southeast Asia). Acquired dRTA is associated with autoimmune diseases (e.g., Sjögren’s syndrome, SLE) or medications (e.g., amphotericin B) [2][4][14].
Onset varies: autosomal recessive forms present in infancy/childhood; autosomal dominant and acquired forms often manifest in adolescence/adulthood [2][6][11].
Burden
Complications: Nephrolithiasis (56%), CKD progression, osteomalacia/rickets, growth failure in children, and sensorineural hearing loss (genetic forms) [2][9][11].
Long-term impact: Chronic treatment adherence is critical; untreated cases risk renal failure [3][6][12].
Economic/psychosocial: Frequent monitoring, lifelong therapy, and reduced quality of life due to recurrent hospitalization and comorbidities [4][6].
Therapies
Alkali therapy: Sodium bicarbonate (1–8 mEq/kg/day) or potassium citrate to correct acidosis, hypokalemia, and reduce stone risk [1][3][12].
Targeted management: Potassium supplementation for hypokalemia; address underlying causes (e.g., immunosuppression for autoimmune-associated dRTA) [3][9][13].
Monitoring: Regular serum electrolytes, urinary calcium/citrate, and renal function to prevent CKD progression [2][6][12].
Categories: rare genetic diseases, rare renal diseases, rare transplant-related disorders
Research Papers
396 drug discovery papers about Distal renal tubular acidosis, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
396 drug discovery papers about Distal renal tubular acidosis, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-10 | Distal Renal Tubular Acidosis in Pregnancy: A Case Report and Systematic Literature Review.
Distal renal tubular acidosis (dRTA) is a rare disorder characterized by normal anion gap metabolic acidosis and hypokalaemia. Physiological changes during pregnancy may aggravate acid-base imbalance and influence foetal outcomes. A 40-year-old pregnant woman at 24-25 weeks of gestation presented with recurrent hypokalaemia and lower limb weakness. Laboratory findings showed normal anion gap metabolic acidosis, consistent with dRTA. The patient was treated with oral potassium supplementation and intravenous sodium bicarbonate, resulting in clinical improvement. In the third trimester, intrauterine growth restriction was identified. Delivery at term resulted in a live neonate with low birth weight.A literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines using PubMed, ScienceDirect, Wiley Online Library, SpringerLink, and ResearchGate for studies published between 2016 and 2026. Ten case reports met the inclusion criteria. Distal RTA was the most frequently reported subtype, accounting for 80% of cases. Most cases (70%) were first diagnosed during pregnancy. The most common treatment strategy was potassium supplementation combined with bicarbonate therapy (90%), administered either orally, intravenously, or as combination therapy. Adverse neonatal outcomes were reported in 50% of cases. Distal RTA should be considered in pregnant patients presenting with recurrent hypokalaemia and muscle weakness. Early recognition and appropriate correction of electrolyte imbalance and metabolic acidosis are essential to optimize maternal and foetal condition. Further studies are needed to better define clinical characteristics and management strategies of renal tubular acidosis during pregnancy. Vigilance is essential for rare distal renal tubular acidosis (dRTA)-pregnancy overlap As the leading form of RTA, (seen in 80% of reported cases), distal RTA (dRTA) frequently first appears during pregnancy (70% of instances), where it closely resembles routine hypokalaemic conditions. Clinicians should routinely check for anion-gap metabolic acidosis in pregnant women experiencing repeated muscle weakness, allowing timely treatment to avert severe maternal decline.Bicarbonate and potassium therapy boosts maternal-foetal success In this case, combined oral and intravenous replacement (effective in 90% of documented scenarios) quickly alleviated symptoms, yet the 50% chance of neonatal issues like intrauterine growth restriction or low birth weight underscores the approach's value for the foetus, providing internists with a reliable, safe strategy amid pregnancy's natural acid-base changes.Diagnostic pathway to reveal hidden dRTA dangers This experience arms internists with a straightforward algorithm (start with hypokalaemia evaluation, advance to acidosis testing) that cuts late-pregnancy risks, especially in settings with limited resources.
2026-06-05 | Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity.
Lithium remains a mainstay of therapy for bipolar disease and refractory depression with future potential for expanded use on the basis of novel data demonstrating its immunomodulatory and neuroprotective effects. This drug accumulates intracellularly via sodium transport pathways, and its effects on complex cellular signaling mechanisms, including glycogen synthase kinase-3 β inhibition, form the basis of its therapeutic efficacy and toxicity. Increased intracellular levels disrupt cellular processes and trigger injury via mitochondrial dysfunction and oxidative stress. Lithium has a narrow therapeutic index and causes dose-dependent nephrotoxicity. A tubulointerstitial pattern of kidney injury is typical; however, lithium can rarely cause glomerular injury as well. An acute rise in serum lithium levels can result in severe volume depletion from lithium-induced natriuresis and aquaresis and cause AKI. Changes in kidney function and various drug interactions can acutely affect serum lithium levels further increasing the risk of toxicity. Arginine vasopressin resistance is the most common complication of chronic lithium use and can be an early manifestation. CKD occurs after a longer latency of over 10 years with a variable slope of GFR decline. Progression to ESKD is relatively low but is affected by the presence of other nephrotoxic risk factors. Epithelial sodium channel blockers such as amiloride can be helpful in mitigating lithium nephrotoxicity by reducing cellular accumulation. Hypercalcemia secondary to lithium-induced hyperparathyroidism is associated with a higher risk of nephrolithiasis and CKD progression. Kidney microcystic changes are common in lithium-induced CKD, and distal renal tubular acidosis can also be seen. Using the lowest effective lithium dose, close monitoring of kidney function and serum lithium levels and early diagnosis of lithium nephrotoxicity is critical in preventing irreversible kidney injury. The decision to discontinue lithium is challenging, and the benefits versus risks must be carefully weighed. This comprehensive review provides a pathogenetic basis and practical clinical framework for diagnosis and management of lithium nephrotoxicity.
2026-06-01 | Distal Renal Tubular Acidosis as a Renal Manifestation of Sjögren's Syndrome: A Case Report.
Distal renal tubular acidosis (dRTA) is a rare but recognized renal complication of Sjögren's syndrome (SS), often resulting from autoimmune-mediated damage to acid-base transporters in the distal nephron. It commonly presents with electrolyte abnormalities including hypokalemia and metabolic acidosis. A 47-year-old woman with chronic kidney disease presented with recurrent hypokalemia, mild proteinuria, and sicca symptoms. Workup revealed non-anion gap metabolic acidosis, a positive urine anion gap, and renal potassium wasting consistent with dRTA. Autoimmune testing showed a high-titer ANA (1:1280) and elevated SSA (>8.0), confirming SS. Renal biopsy revealed mild interstitial fibrosis and glomerulosclerosis without evidence of tubulointerstitial nephritis or immune complex deposition. This finding supports prior evidence that SS-associated dRTA may occur secondary to functional tubular defects involving distal nephron transporters, even in the absence of overt inflammatory histologic changes. Acid-base disturbances improved with potassium and bicarbonate supplementation. This case highlights that significant tubular dysfunction in SS may occur despite minimal or absent histologic evidence of tubulointerstitial nephritis. dRTA in SS may result from autoimmune targeting of distal nephron transporters such as H⁺-ATPase and anion exchanger 1. Early recognition and supportive treatment are essential to prevent complications including nephrolithiasis, progressive kidney dysfunction, and life-threatening hypokalemia. SS should be considered in patients presenting with unexplained dRTA, and timely correction of electrolyte abnormalities is critical to optimizing outcomes.
2026-06-10 | Distal Renal Tubular Acidosis in Pregnancy: A Case Report and Systematic Literature Review.
Distal renal tubular acidosis (dRTA) is a rare disorder characterized by normal anion gap metabolic acidosis and hypokalaemia. Physiological changes during pregnancy may aggravate acid-base imbalance and influence foetal outcomes. A 40-year-old pregnant woman at 24-25 weeks of gestation presented with recurrent hypokalaemia and lower limb weakness. Laboratory findings showed normal anion gap metabolic acidosis, consistent with dRTA. The patient was treated with oral potassium supplementation and intravenous sodium bicarbonate, resulting in clinical improvement. In the third trimester, intrauterine growth restriction was identified. Delivery at term resulted in a live neonate with low birth weight.A literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines using PubMed, ScienceDirect, Wiley Online Library, SpringerLink, and ResearchGate for studies published between 2016 and 2026. Ten case reports met the inclusion criteria. Distal RTA was the most frequently reported subtype, accounting for 80% of cases. Most cases (70%) were first diagnosed during pregnancy. The most common treatment strategy was potassium supplementation combined with bicarbonate therapy (90%), administered either orally, intravenously, or as combination therapy. Adverse neonatal outcomes were reported in 50% of cases. Distal RTA should be considered in pregnant patients presenting with recurrent hypokalaemia and muscle weakness. Early recognition and appropriate correction of electrolyte imbalance and metabolic acidosis are essential to optimize maternal and foetal condition. Further studies are needed to better define clinical characteristics and management strategies of renal tubular acidosis during pregnancy. Vigilance is essential for rare distal renal tubular acidosis (dRTA)-pregnancy overlap As the leading form of RTA, (seen in 80% of reported cases), distal RTA (dRTA) frequently first appears during pregnancy (70% of instances), where it closely resembles routine hypokalaemic conditions. Clinicians should routinely check for anion-gap metabolic acidosis in pregnant women experiencing repeated muscle weakness, allowing timely treatment to avert severe maternal decline.Bicarbonate and potassium therapy boosts maternal-foetal success In this case, combined oral and intravenous replacement (effective in 90% of documented scenarios) quickly alleviated symptoms, yet the 50% chance of neonatal issues like intrauterine growth restriction or low birth weight underscores the approach's value for the foetus, providing internists with a reliable, safe strategy amid pregnancy's natural acid-base changes.Diagnostic pathway to reveal hidden dRTA dangers This experience arms internists with a straightforward algorithm (start with hypokalaemia evaluation, advance to acidosis testing) that cuts late-pregnancy risks, especially in settings with limited resources.
2026-06-05 | Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity.
Lithium remains a mainstay of therapy for bipolar disease and refractory depression with future potential for expanded use on the basis of novel data demonstrating its immunomodulatory and neuroprotective effects. This drug accumulates intracellularly via sodium transport pathways, and its effects on complex cellular signaling mechanisms, including glycogen synthase kinase-3 β inhibition, form the basis of its therapeutic efficacy and toxicity. Increased intracellular levels disrupt cellular processes and trigger injury via mitochondrial dysfunction and oxidative stress. Lithium has a narrow therapeutic index and causes dose-dependent nephrotoxicity. A tubulointerstitial pattern of kidney injury is typical; however, lithium can rarely cause glomerular injury as well. An acute rise in serum lithium levels can result in severe volume depletion from lithium-induced natriuresis and aquaresis and cause AKI. Changes in kidney function and various drug interactions can acutely affect serum lithium levels further increasing the risk of toxicity. Arginine vasopressin resistance is the most common complication of chronic lithium use and can be an early manifestation. CKD occurs after a longer latency of over 10 years with a variable slope of GFR decline. Progression to ESKD is relatively low but is affected by the presence of other nephrotoxic risk factors. Epithelial sodium channel blockers such as amiloride can be helpful in mitigating lithium nephrotoxicity by reducing cellular accumulation. Hypercalcemia secondary to lithium-induced hyperparathyroidism is associated with a higher risk of nephrolithiasis and CKD progression. Kidney microcystic changes are common in lithium-induced CKD, and distal renal tubular acidosis can also be seen. Using the lowest effective lithium dose, close monitoring of kidney function and serum lithium levels and early diagnosis of lithium nephrotoxicity is critical in preventing irreversible kidney injury. The decision to discontinue lithium is challenging, and the benefits versus risks must be carefully weighed. This comprehensive review provides a pathogenetic basis and practical clinical framework for diagnosis and management of lithium nephrotoxicity.
2026-06-01 | Distal Renal Tubular Acidosis as a Renal Manifestation of Sjögren's Syndrome: A Case Report.
Distal renal tubular acidosis (dRTA) is a rare but recognized renal complication of Sjögren's syndrome (SS), often resulting from autoimmune-mediated damage to acid-base transporters in the distal nephron. It commonly presents with electrolyte abnormalities including hypokalemia and metabolic acidosis. A 47-year-old woman with chronic kidney disease presented with recurrent hypokalemia, mild proteinuria, and sicca symptoms. Workup revealed non-anion gap metabolic acidosis, a positive urine anion gap, and renal potassium wasting consistent with dRTA. Autoimmune testing showed a high-titer ANA (1:1280) and elevated SSA (>8.0), confirming SS. Renal biopsy revealed mild interstitial fibrosis and glomerulosclerosis without evidence of tubulointerstitial nephritis or immune complex deposition. This finding supports prior evidence that SS-associated dRTA may occur secondary to functional tubular defects involving distal nephron transporters, even in the absence of overt inflammatory histologic changes. Acid-base disturbances improved with potassium and bicarbonate supplementation. This case highlights that significant tubular dysfunction in SS may occur despite minimal or absent histologic evidence of tubulointerstitial nephritis. dRTA in SS may result from autoimmune targeting of distal nephron transporters such as H⁺-ATPase and anion exchanger 1. Early recognition and supportive treatment are essential to prevent complications including nephrolithiasis, progressive kidney dysfunction, and life-threatening hypokalemia. SS should be considered in patients presenting with unexplained dRTA, and timely correction of electrolyte abnormalities is critical to optimizing outcomes.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Distal renal tubular acidosis.
2 orphan drug designations for Distal renal tubular acidosis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
fixed-dose combination of potassium citrate and potassium bicarbonate | small molecules | FDA | 2022-12-09 | — | Advicenne |
Potassium citrate monohydrate, Potassium hydrogen carbonate [Sibnayal] | small molecules | EMA | 2017-06-20 | — | [INACTIVE] Advicenne |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.